
    
      Omalizumab is indicated in children over 6 years of age, with diagnosis of difficult to
      control asthma, presenting a component of atopy demonstrated preferably positive skin tests
      (prick test) or in vitro reactivity (rast) allergens common inhalants. Patients must also
      present the total serum IgE levels between 30 and 700UI/mL. Children until 12 years the IgE
      level is between 30 and 300 IU/ml.
    
  